Specialty Pharma

A specialty pharmaceutical company has experienced a dramatic EBITDA margin collapse — from 28% to 13% over three years — despite strong revenue growth from $400M to $560M. The candidate must identify the drivers of rising costs and recommend corrective actions. This is a profitability case with a life sciences context, requiring clean cost decomposition and synthesis.

Client: A specialty pharma company operating in the branded/differentiated therapeutics space. Situation: Revenue has grown meaningfully over three years, yet profitability has more than halved. Leadership is concerned and has hired the consulting team to diagnose the issue. Firm context: L.E.K. Consulting — candidate-led format. Life sciences and PE due diligence are core L.E.K. sectors. Timeframe: Three-year performance window being analyzed.

The client's EBITDA margin has declined from 28% to 13% over three years, even as revenue grew from $400M to $560M. In absolute terms, EBITDA has fallen from $112M to $72.8M — a drop of ~$39M — despite $160M in additional revenue. The company is spending more than $1.25 for every $1.00 of incremental revenue generated. The core question is: what is driving this cost overrun, and how should it be addressed?

Step 1 — Quantify: Anchor the analysis with absolute EBITDA and cost figures before diagnosing. Year 1: $112M EBITDA on $288M costs. Year 3: $72.8M EBITDA on $487.2M costs. Cost grew $199.2M to generate $160M in revenue — confirming cost is the core issue, not revenue shortfall. Step 2 — Decompose: Break the cost base into COGS (variable), SG&A (semi-fixed), and R&D (investment). Apply the provided percentages to isolate which line is out of control. Step 3 — Diagnose root cause: SG&A is the primary driver — it grew from 20% to 31% of revenue (+$93.6M), roughly half the total EBITDA loss. The hypothesis: over-expansion of the commercial/sales organization without proportional revenue return. Step 4 — Recommend: Conduct a SG&A efficiency audit focused on sales force productivity by territory. Benchmark versus the pharma peer median (~20–22% of revenue). Identify and restructure or exit the lowest revenue-per-rep territories. Separately, evaluate R&D portfolio for low-priority spend that can be deferred or cut. Final recommendation (synthesis-ready format): The core issue is SG&A over-expansion — the company added $93.6M in selling costs while generating $160M in revenue growth. I recommend a SG&A efficiency audit benchmarked against the pharma peer median of 20–22% of revenue. The immediate lever is a territory-level productivity analysis to identify and restructure the lowest-performing markets. If SG&A returns to 22% of Year 3 revenue, that alone recovers ~$50M in EBITDA — restoring margin above 20%.